**Summary**
Abingdon Health plc, a UK-based med-tech company specializing in rapid diagnostic <mark style="background-color:yellow">test</mark>s and contract development and manufacturing (CDMO) services, announced a retail offer of new ordinary shares to raise up to £200,000. The offer, priced at 6 pence per share, is open to existing retail shareholders in the United Kingdom, with a minimum subscription of £100 per investor. The retail offer runs from October 14 to October 16, 2025, and is part of a larger fundraising effort that includes a placing of shares to institutional investors, aiming to raise up to £3.34 million in total.
The funds raised will support the expansion of Abingdon Healths lateral flow manufacturing capacity in the USA and provide working capital for executing larger CDMO contracts. The retail offer is managed through the BookBuild platform, with Zeus Capital Limited acting as the retail offer coordinator. Shares issued under the retail offer will rank equally with existing ordinary shares and are expected to be admitted to trading on October 31, 2025.
The offer is subject to specific eligibility criteria, including residency in the UK and existing share ownership in the company. It is not available to US persons or in jurisdictions where it would violate local laws. The company emphasizes the risks associated with the investment and advises investors to seek independent advice. The announcement also includes important notices regarding regulatory compliance, product governance, and disclaimers related to forward-looking statements and investment risks.